International Journal of Clinical Pharmacy

, Volume 41, Issue 1, pp 18–21 | Cite as

Infectious diseases physician attitudes to long-term antibiotic use

  • Christopher R. Kiss
  • Jillian S. Y. Lau
  • Alex Yeung
  • Ian WoolleyEmail author
Short Research Report


Background In Australia, it is not known how much antibiotic prescribing by infectious diseases physicians is long-term, or how confident they are with the evidence behind this practice. Objective Survey Australian infectious diseases physicians to assess attitudes and prescribing practice prescribing prolonged courses of antibiotics. Methods An online questionnaire was distributed to the mailing group for the Australian Society of Infectious Diseases. Responses were collected from 29th October to 12th November 2015. Results The majority of respondents practiced in Australia as Infectious Diseases physicians, microbiologists, or trainees. 88% had prescribed long-term antibiotics. Heterogeneity was noted in the indications for prescription, including recurrent UTIs, cellulitis or chest infections, prosthetic joint infection and vascular graft infection. Beta-lactams antibiotics were prescribed most frequently. 22% of respondents had prescribed rifampicin/fusidic acid most frequently, while 11% could not identify a single antibiotic that they used most frequently, due to the heterogeneity of indications for prescribing. 95% stated that they would stop long-term antibiotic therapy if appropriate, and 74% were willing to enrol their patients into a randomised control trial looking at stopping long-term therapy. Conclusion Most infectious diseases physicians who responded to the survey prescribe long-term antibiotics, with great heterogeneity in the indications for which these antibiotics are prescribed.


Antimicrobial stewardship Antimicrobials Australia Infectious diseases specialists Long term prescribing Questionnaire 



No funding was received for this study.

Conflicts of interest

There are no conflicts of interest amongst those involved in the study.

Supplementary material

11096_2018_781_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (14 KB)


  1. 1.
    Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis. 2011;13:551–8.Google Scholar
  2. 2.
    Dason S, Dason J, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J. 2011;5:316–22.Google Scholar
  3. 3.
    Stapleton A, Stamm W. Prevention of urinary tract infection. Infect Dis Clin North Am. 1997;11:719–33.Google Scholar
  4. 4.
    Jones P, Woolley I, Leder K, Spelman D, Cameron P, Cheng A. Postsplenectomy infection; strategies for prevention in general practice. Aust Fam Physician. 2010;39(6):383.Google Scholar
  5. 5.
    Osman D, Berbari E, Berendt A, Lew D, ZImmerli W, Steckelberg J. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infection diseases Society of Amrica. Clin Infect Dis. 2012;56(1):e1–25.Google Scholar
  6. 6.
    Baddour L. Long-term suppressive antimicrobial therapy for intravascular device-related infections. Am J Med Sci. 2001;322(4):209–12.Google Scholar
  7. 7.
    Lau J, Kiss C, Roberts E, Horne K, Korman T, Woolley I. Surveillance of life-long. antibiotics: a review of antibiotic prescribing practices in an Australian Healthcare Network. Ann Clin Microbiol Antimicrob. 2017;16:3.Google Scholar
  8. 8.
    Survey Monkey, 2018. Available from:
  9. 9.
    Ozbug, 2018. Available from:
  10. 10.
    Watson D. Ozbug: an email mailing list for physicians that works. Intern Med J. 2003;33(11):532–4.Google Scholar
  11. 11.
    Pushkin R, Iglesias-Ussel M, Keedy K, MacLauchlin C, Mould D, Berkowitz R, et al. A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of- care antibiotics for treatment of prosthetic joint infections: a newly identified drug–drug interaction. Clin Infect Dis. 2016;15(12):1599–604.Google Scholar
  12. 12.
    Lau JSY, Korman TM, Woolley I. Life-long antimicrobial therapy: where is the evidence? J Antimicrob Chemother. 2018;73(10):2601–12.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Monash HealthClaytonAustralia
  2. 2.Department of Infectious DiseasesAlfred HospitalPrahranAustralia
  3. 3.Monash UniversityClaytonAustralia
  4. 4.Monash Infectious Diseases, Monash Medical CentreClaytonAustralia

Personalised recommendations